When Can Adults Safely Stop MOG Antibody Treatment?

Credibility

Interest

Key Takeaway

Stopping long-term immune treatment in some adults with MOG antibody disease led to a low short-term risk of relapse, especially if treatment lasted more than a year and the last relapse was over two years ago.

What They Found

Researchers looked at 83 adults with MOG antibody disease who stopped maintenance treatment either on purpose or because of side effects. Only 7 people had the disease come back within a year after stopping, so most patients stayed relapse-free in the short term. When relapses did happen, they were generally mild and did not cause big jumps in disability scores. People who had been on treatment for less than one year, or who had a relapse within the past two years, were more likely to have the disease return after stopping. These results suggest that carefully chosen adults might safely pause treatment, but this was a backward-looking study and not a randomized trial.

Who Should Care and Why

People with MOG antibody disease and their caregivers should care because stopping treatment can lower risks from long-term immune-suppressing drugs, like infections or medication side effects. Neurologists and MS/MOG specialists will find this useful when talking about when and how to stop medicines, similar to deciding when to take a break from a tool you no longer need. Patients who have been stable for more than two years and who have been on a treatment for over a year may benefit most from considering stopping under medical supervision. Caregivers should know that stopping treatment doesn't mean immediate danger for most people, but close follow-up is important—like watching a plant closely after moving it to a new spot. This could affect day-to-day life by reducing medication costs, side effects, and the need for frequent drug monitoring if a doctor agrees stopping is safe.

Important Considerations

This study looked back at past medical records (retrospective) and was not a randomized trial, so it can suggest associations but cannot prove cause and effect. The number of people who stopped treatment and then relapsed was small, so the results are less certain for some subgroups and for long-term risk beyond one year. Because treatments, reasons for stopping, and patient health varied, decisions about stopping should be personalized and made together with a doctor who will plan careful follow-up.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Progression Clinical Trials

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News